Malignant peripheral nerve sheath tumor (MPNST) is a high-grade malignant sarcoma arising from peripheral nerves or pre-existing neurofibroma. Risk in NF1 patients is 8-13%, presenting at earlier age than sporadic cases. Usually involves large nerves (sciatic, brachial plexus, lumbar plexus). Rapid growth, pain, and neurological deficit are clinical warning signs. On imaging, it appears as a heterogeneous, necrotic, large mass; target sign is lost — this is the most reliable imaging indicator of malignant transformation from benign neurofibroma. SUVmax >3.5 on PET-CT is considered gold standard for benign/malignant differentiation. 5-year survival ranges from 20-50% and is worse in NF1-associated cases.
Age Range
20-55
Peak Age
35
Gender
Equal
Prevalence
Rare
MPNST develops from NF1 gene inactivation background with additional genetic aberrations (TP53, CDKN2A, SUZ12, EED loss). PRC2 (Polycomb Repressive Complex 2) loss leads to epigenetic deregulation and aggressive tumor phenotype — H3K27me3 (histone 3 lysine 27 trimethylation) loss is used as diagnostic marker in immunohistochemistry. In malignant transformation from existing neurofibroma, target sign is lost because the tumor's zonal histological structure (central fibrosis + peripheral myxoid) is disrupted — aggressive cell proliferation destroys the homogeneous structure creating a heterogeneous mass. Necrosis develops as rapid growth exceeds vascular capacity — ischemic necrosis forms centrally. Diffusion restriction increases due to markedly elevated cellular density — malignant cells are small and densely packed. Perineural spread is an aggressive growth pattern where tumor progresses along the nerve sheath, appearing as thickening and enhancement along nerve course on MRI, directly affecting surgical margin planning.
Disappearance of previously present target sign on MRI follow-up with simultaneous development of new diffusion restriction (low ADC) is the most reliable imaging finding combination for malignant transformation from neurofibroma to MPNST. Target sign loss + size increase + new diffusion restriction + SUVmax >3.5 should be evaluated together — coexistence of these four findings definitively confirms malignant transformation.
On T2, MPNST shows markedly heterogeneous signal. The target sign present in benign neurofibroma is lost. Solid areas show intermediate-to-high T2 signal, necrotic areas very high T2, hemorrhagic areas low T2. Perineural spread may be seen as thickening along nerve course. Heterogeneity reflects mixture of viable tumor, necrosis, and hemorrhage in different parts of the tumor.
Report Sentence
The mass shows markedly heterogeneous T2 signal without target sign; necrotic areas present; MPNST should be considered.
On DWI, MPNST shows marked diffusion restriction in solid components. ADC values are low (0.6-1.0 × 10⁻³ mm²/s) — significantly lower than benign neurofibroma (1.5-2.5). This difference is the most reliable quantitative MRI indicator of malignant transformation. ADC 1.0 cutoff shows 87% sensitivity and 85% specificity for benign/malignant differentiation.
Report Sentence
Marked diffusion restriction (ADC: ___ × 10⁻³ mm²/s) is seen in solid components of the mass, suggesting malignant transformation.
On FDG PET-CT, MPNST shows high FDG uptake (SUVmax typically >3.5, often >5-8). SUVmax >3.5 cutoff is considered gold standard for differentiating MPNST from benign neurofibroma with >90% accuracy. Heterogeneous uptake pattern distinguishes necrotic areas (FDG negative) from viable tumor (FDG positive). In NF1 patients, PET-CT is the most valuable modality for identifying the lesion transforming to MPNST among multiple neurofibromas.
Report Sentence
High FDG uptake (SUVmax: ___) is seen in the mass; above 3.5 threshold consistent with MPNST.
On contrast-enhanced CT, MPNST appears as a large (usually >5 cm), heterogeneously enhancing mass. Necrotic areas are prominent and show no enhancement. Irregular margins and invasion of surrounding structures may be seen. Unlike homogeneous mild enhancement of benign neurofibroma, it shows intense and heterogeneous enhancement. Entering/exiting nerve sign (nerve enters and exits the mass) confirms neurogenic origin.
Report Sentence
A large, heterogeneously enhancing, necrotic retroperitoneal mass is seen; aggressive peripheral nerve sheath tumor (MPNST) should be considered.
On contrast-enhanced MRI, irregular, heterogeneous enhancement is seen. As a sign of perineural spread, abnormal thickening and enhancement along nerve course may be seen — critical for surgical planning and resection margins, making negative surgical margins difficult to achieve. Fat-suppressed post-contrast T1 sequences best demonstrate perineural spread. Non-enhancing necrotic areas are scattered within viable tumor.
Report Sentence
The mass shows irregular enhancement with findings of perineural spread along the nerve course.
On T1 or T2-weighted MR images, the nerve entering and exiting the mass may be visualized — entering/exiting nerve sign. This finding confirms the neurogenic origin of the tumor and proves that MPNST arises from a peripheral nerve. The nerve appears as a thin-caliber structure compared to the mass as it enters and exits. Coronal and sagittal MR sections best demonstrate this finding.
Report Sentence
A nerve structure entering and exiting the mass is visualized, confirming neurogenic origin.
Criteria
On NF1 background, transformation from existing neurofibroma, younger age (20-40), may be bilateral
Distinct Features
Growing lesion on background of multiple neurofibromas, worse prognosis (5-year survival 20-35%), whole body PET-CT screening recommended
Criteria
De novo development without NF1, usually age 40-60, along large nerves
Distinct Features
Solitary lesion, relatively better prognosis than NF1-associated (5-year survival 40-50%), no pre-existing neurofibroma history
Criteria
Development in prior radiotherapy field (latent period 10-20 years), usually high-grade, poor prognosis
Distinct Features
Correlation with radiation field, long latent period, poor prognosis, classified as treatment-related secondary malignancy
Distinguishing Feature
Benign neurofibroma SUVmax <3.5, target sign preserved, homogeneous T2, no diffusion restriction (ADC >1.5); MPNST SUVmax >3.5, target sign lost, heterogeneous T2, diffusion restriction present (ADC <1.0)
Distinguishing Feature
Leiomyosarcoma shows no nerve relationship (no entering/exiting nerve sign), may involve IVC; MPNST grows along nerve course and shows entering/exiting nerve sign
Distinguishing Feature
UPS shows no specific nerve relationship and no NF1 context; MPNST shows entering/exiting nerve sign, perineural spread and NF1 clinical context
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
3-monthMPNST is an aggressive sarcoma requiring multidisciplinary approach. Wide surgical resection (R0 — negative surgical margin) is optimal treatment but nerve preservation and neurological deficit balance must be considered — negative margins may be difficult to achieve due to perineural spread and intraoperative frozen section is recommended. Adjuvant radiotherapy (50-60 Gy) is applied in R1 resection or high-grade tumors. Chemotherapy (doxorubicin/ifosfamide) is considered in large, high-grade, or metastatic tumors but response rate is low (15-25%). Prognosis is worse in NF1 patients (5-year survival 20-35%) and aggressive follow-up is required. Metastasis most commonly to lung — CT lung surveillance is mandatory. Annual whole-body MRI and/or PET-CT screening is recommended in NF1 patients — early detection of transforming lesion among multiple neurofibromas improves survival.
MPNST is an aggressive tumor. Lifetime risk in NF1 patients is 8-13%. Wide surgical resection and adjuvant radiotherapy form the mainstay of treatment. 5-year survival is 35-50%. Distant metastasis most commonly occurs to the lungs.